---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283182"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:01.626575+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# enGene prices $130M public offering of common shares and pre-funded warrants

## Summary
- Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.
- Gross proceeds expected ~$130M before underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 2,294,117 additional common shares.
- Offering expected to close on or about November 14, 2025.
- Proceeds to advance clinical-stage genetic medicines pipeline, including lead NMIBC candidate detalimogene.

## SEC filing metadata
- accession: 0001193125-25-283182
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/0001193125-25-283182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283182
- JSON: https://secwatch.observer/filing/0001193125-25-283182.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.